Costa A, Lemes R, Bartolomeo C, Nunes T, Pereira G, Oliveira R, et al. Overexpression of estrogen receptor GPER1 and G1 treatment reduces SARS-CoV-2 infection in BEAS-2B bronchial cells. Mol Cell Endocrinol. 2022;558:111775 pubmed publisher

Li X, Zhuo S, Zhuang T, Cho Y, Wu G, Liu Y, et al. YAP inhibits ERα and ER+ breast cancer growth by disrupting a TEAD-ERα signaling axis. Nat Commun. 2022;13:3075 pubmed publisher

Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit N, Ding K, et al. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022;13:2011 pubmed publisher

Barua D, Abbasi B, Gupta A, Gupta S. XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation. Heliyon. 2020;6:e05217 pubmed publisher

Chapple R, Hu T, Tseng Y, Liu L, Kitano A, Luu V, et al. ERα promotes murine hematopoietic regeneration through the Ire1α-mediated unfolded protein response. elife. 2018;7: pubmed publisher

Yang H, Yu N, Xu J, Ding X, Deng W, Wu G, et al. SMURF1 facilitates estrogen receptor ɑ signaling in breast cancer cells. J Exp Clin Cancer Res. 2018;37:24 pubmed publisher

Shi J, Chen S, Guo C, Li Y, Ding J, Meng L. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. Acta Pharmacol Sin. 2018;39:1338-1346 pubmed publisher

Lahsaee S, Corkery D, Anthes L, Holly A, Dellaire G. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. Exp Cell Res. 2016;340:125-31 pubmed publisher